Ultragenyx Pharmaceutical announced the sale of a Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million. This transaction monetizes an asset received from the FDA approval of their gene therapy, GENGLYCOS, providing a significant cash infusion for the company.
Ultragenyx Pharmaceutical has sold its Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million. This PRV was awarded upon the FDA approval of their gene therapy, GENGLYCOS, for glycogen storage disease type Ia (GSDIa). The sale provides a substantial, non-dilutive cash injection for Ultragenyx, which can be used to fund ongoing research and development, commercialization efforts, or general corporate purposes. For traders, this is a positive short-term event as it strengthens the company's balance sheet and validates the value of their approved therapy. The long-term implication is that this cash can support future growth initiatives, reducing the need for immediate equity financing.